Difference between revisions of "About-cancer/treatment/drugs/caplacizumab-yhdp/zh"
(Created page with "'''FDA批准'''") |
(Created page with "是") |
||
| Line 10: | Line 10: | ||
'''FDA批准''' | '''FDA批准''' | ||
| − | + | 是 | |
FDA label information for this drug is available at DailyMed. | FDA label information for this drug is available at DailyMed. | ||
Revision as of 16:25, 4 November 2019
卡帕珠单抗
本页包含有关caplacizumab-yhdp的简要信息，以及一些链接，这些链接指向有关该药物的用途，研究结果和正在进行的临床试验的更多信息。
美国品牌名称
卡布利维
FDA批准
是
FDA label information for this drug is available at DailyMed.
Use in Cancer
Caplacizumab-yhdp is approved to treat:
- Acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It is used with plasma exchange and immunosuppressive therapy.
More About Caplacizumab-yhdp
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trials Accepting Patients
Find Clinical Trials for Caplacizumab-yhdp - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
